A global provider of high-quality APIs Weifa is a leading provider of APIs (Active Pharmaceutical Ingredients) to the global pharmaceutical industry. The offering is centered on two key products: Metformin for use in diabetes II medication and Opioids for use in pain treatment. Since 1969, Weifa has built significant capacity and expertise as an API provider. Production takes place at the company’s two facilities in Kragerø, Norway, both certified according to Good Manufacturing Practice (GMP) and successfully inspected by the US Food and Drug Administration (FDA) in 2011. The products are marketed in more than 50 countries around the world. Pharmacopoeia Metformin Weifa commands around 8 percent of the global market for metformin, an active ingredient in first-line treatment of diabetes II. Opioids Weifa serves the world market for Opioid APIs with two key products. Customer service Weifa’s strong international position as an API provider rests on more than top quality products.